AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10423978 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions in endocrinology, nephrology, haematology, and oncology
Number of subjects: 197
Study 10423978 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of patients presenting with symptoms only, without a specific diagnosis
Number of subjects: 197
Study 8835086 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (10 micrograms/kg/min)
Number of subjects: 20
Study 8835086 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (10 micrograms/kg/min)
Number of subjects: 20
Study 2351001 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 percent bupivacaine (1.5 mg/kg) in adrenaline solution (1:200,000)
Number of subjects: 40
Study 2351001 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline solution (control)
Number of subjects: 40
Study 356306 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (10 mg/kg, three doses: upon admission, 8 hours, and 16 hours post-trauma)
Number of subjects: 60
Study 356306 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 60
Study 356306 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 60
Study 29437598 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral TENS+TOT
Number of subjects: 80
Study 29437598 — intervention group
Group type: COMPARATOR
Intervention: Unilateral TENS+TOT
Number of subjects: 80
Study 27876031 — intervention group
Group type: EXPERIMENTAL
Intervention: NEXit intervention (text messaging-based smoking cessation programme)
Number of subjects: 289
Study 27876031 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 289
Study 25407464 — intervention group
Group type: EXPERIMENTAL
Intervention: Single MDA with azithromycin
Number of subjects: 0
Study 25407464 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual MDA with azithromycin
Number of subjects: 0
Study 25407464 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 0
Study 23359969 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxiao Jiuxin Pill (SJP) and Western medicine
Number of subjects: 60
Study 23359969 — intervention group
Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 60
Study 20374661 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered lifestyle intervention promoting healthy weight and physical activity (4 sessions over 8 weeks)
Number of subjects: 0
Study 20374661 — intervention group
Group type: COMPARATOR
Intervention: Control group (previously proven physical activity intervention, 2 sessions over 6 weeks)
Number of subjects: 0
Study 17652708 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% azithromycin in DuraSite (n = 365)
Number of subjects: 743
Study 17652708 — intervention group
Group type: COMPARATOR
Intervention: 0.3% tobramycin (n = 378)
Number of subjects: 743
Study 16105793 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective induction of labor (IND)
Number of subjects: 226
Study 16105793 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (EM)
Number of subjects: 226
Study 16105793 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective induction of labor (IND) for nulliparous patients
Number of subjects: 226
Study 16105793 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (EM) for nulliparous patients
Number of subjects: 226
Study 12105285 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 300 mg/d
Number of subjects: 327
Study 12105285 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 400 mg/d
Number of subjects: 327
Study 12105285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study 10457876 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-guided tracheal intubation using a prototype illuminated flexible catheter
Number of subjects: 100
Study 10457876 — intervention group
Group type: COMPARATOR
Intervention: Blind tracheal intubation through the intubating laryngeal mask
Number of subjects: 100
Study 7794581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 2171046 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide histidine valine (PHV) infusion
Number of subjects: 4
Study 2171046 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (beta-blocker)
Number of subjects: 4
Study 2171046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 387279 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin-DNA (ADM-DNA)
Number of subjects: 69
Study 387279 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin-DNA (DNR-DNA)
Number of subjects: 69
Study 387279 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin (DNR)
Number of subjects: 69
Study 387279 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin (ADM)
Number of subjects: 69
Study 31221493 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic manipulation
Number of subjects: 2024
Study 31221493 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient record scanning
Number of subjects: 2024
Study 31221493 — intervention group
Group type: EXPERIMENTAL
Intervention: Training clinic staff
Number of subjects: 2024
Study 27989730 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention targeting physical activity over a 3-month period.
Number of subjects: 40
Study 27989730 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 40
Study 25059694 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endovascular aneurysm treatment within 24 hours of randomization
Number of subjects: 14
Study 25059694 — intervention group
Group type: COMPARATOR
Intervention: Treatment after neurologic recovery
Number of subjects: 14
Study 23349099 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione (used for in vitro reduction of ovomucoid)
Number of subjects: 19
Study 23349099 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced ovomucoid
Number of subjects: 19
Study 21216083 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for three years
Number of subjects: 68
Study 21216083 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine for three years
Number of subjects: 68
Study 21216083 — intervention group
Group type: COMPARATOR
Intervention: Passive smoking exposure
Number of subjects: 68
Study 19504120 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min repetitive work (RW)
Number of subjects: 15
Study 19504120 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min repetitive work with superimposed mental load (RWML)
Number of subjects: 15
Study 16496196 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults (14); 20% MVC, constant force condition
Number of subjects: 27
Study 16496196 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults (14); 40% MVC, constant force condition
Number of subjects: 27
Study 16496196 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults (14); sinusoidal force condition
Number of subjects: 27
Study 16496196 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults (14); digit force sharing
Number of subjects: 27
Study 16496196 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults (14); cross-correlation analyses
Number of subjects: 27
Study 16496196 — intervention group
Group type: COMPARATOR
Intervention: Young adults (13); 20% MVC, constant force condition
Number of subjects: 27
Study 16496196 — intervention group
Group type: COMPARATOR
Intervention: Young adults (13); 40% MVC, constant force condition
Number of subjects: 27
Study 16496196 — intervention group
Group type: COMPARATOR
Intervention: Young adults (13); sinusoidal force condition
Number of subjects: 27
Study 16496196 — intervention group
Group type: COMPARATOR
Intervention: Young adults (13); digit force sharing
Number of subjects: 27
Study 16496196 — intervention group
Group type: COMPARATOR
Intervention: Young adults (13); cross-correlation analyses
Number of subjects: 27
Study 14579083 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliprobe method (14C-urea breath test)
Number of subjects: 75
Study 14579083 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard method (14C-urea breath test)
Number of subjects: 75
Study 14579083 — intervention group
Group type: COMPARATOR
Intervention: CLO test
Number of subjects: 75
Study 11090597 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-adapt
Number of subjects: 8
Study 11090597 — intervention group
Group type: COMPARATOR
Intervention: HCHO
Number of subjects: 8
Study 9421820 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallelogram goniometer
Number of subjects: 60
Study 9421820 — intervention group
Group type: COMPARATOR
Intervention: Universal goniometer
Number of subjects: 60
Study 7827834 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg intramuscular
Number of subjects: 154
Study 7827834 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 100 mg intramuscular
Number of subjects: 154
Study 3059842 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine with 1/200,000 adrenaline
Number of subjects: 60
Study 3059842 — intervention group
Group type: COMPARATOR
Intervention: 0.5% plain bupivacaine
Number of subjects: 60
Study 29178284 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide inhalations (160 ppm for 30 min, 5 times/day)
Number of subjects: 43
Study 29178284 — intervention group
Group type: COMPARATOR
Intervention: Control (oxygen/air)
Number of subjects: 43
Study 26290001 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM)
Number of subjects: 158
Study 26290001 — intervention group
Group type: COMPARATOR
Intervention: Wait-list comparison group
Number of subjects: 158
Study 23276249 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-laparoscopic cholecystectomy (MLC)
Number of subjects: 41
Study 23276249 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (LC)
Number of subjects: 41
Study 20806100 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoVac for 210 seconds
Number of subjects: 50
Study 20806100 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoVac for 150 seconds
Number of subjects: 50
Study 20806100 — intervention group
Group type: COMPARATOR
Intervention: Traditional positive-pressure irrigation for 210 seconds
Number of subjects: 50
Study 18812629 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg 30 min prior to ASA)
Number of subjects: 21
Study 18812629 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (0.5 g 30 min prior to ASA)
Number of subjects: 21
Study 18812629 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (2 x 1 g daily)
Number of subjects: 21
Study 15883439 — intervention group
Group type: EXPERIMENTAL
Intervention: Step I diet supplemented with soy food (SFD; 50 mg isoflavones/d)
Number of subjects: 57
Study 15883439 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-fat diet (VLFD; 11% of energy as fat)
Number of subjects: 57
Study 15883439 — intervention group
Group type: COMPARATOR
Intervention: Control Step I diet (CD; 27% of energy as fat)
Number of subjects: 57
Study 12932663 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined definition of melanoma ulceration
Number of subjects: 0
Study 12932663 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized pathology worksheet for reporting primary melanomas
Number of subjects: 0
Study 11279318 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates
Number of subjects: 1303
Study 11279318 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment
Number of subjects: 1303
Study 11279318 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates (in Killip class II‐IV patients)
Number of subjects: 1303
Study 11279318 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment (in Killip class II‐IV patients)
Number of subjects: 1303
Study 8600428 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% tropicamide
Number of subjects: 40
Study 8600428 — intervention group
Group type: COMPARATOR
Intervention: Control (young and older subjects)
Number of subjects: 40
Study 1720478 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (1.25 mg or 2.5 mg twice daily)
Number of subjects: 231
Study 1720478 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (12.5 mg or 25 mg twice daily)
Number of subjects: 231
Study 1720478 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of isradipine and captopril
Number of subjects: 231
Study 7326194 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (CP) 2 mg injection
Number of subjects: 43
Study 7326194 — intervention group
Group type: COMPARATOR
Intervention: Control (no immune stimulation)
Number of subjects: 43
Study 30329136 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized monthly coaching by a physical therapist to adhere to 30 minutes of daily physical activity and 45 minutes of weekly exercise over 18 months
Number of subjects: 186
Study 28466419 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-Shoulder Resistance Exercise (NSRE)
Number of subjects: 35
Study 28466419 — intervention group
Group type: COMPARATOR
Intervention: Conventional Stretching and Postural Exercise (SPE)
Number of subjects: 35
Study 25498738 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD-based intervention for stroke self-management over 8 weeks
Number of subjects: 20
Study 25498738 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 20
Study 22858517 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day concomitant therapy comprising esomeprazole 40 mg, amoxicillin 1000 mg, clarithromycin 500 mg, and metronidazole 500 mg, all bid
Number of subjects: 257
Study 22858517 — intervention group
Group type: COMPARATOR
Intervention: 10-day standard triple therapy comprising esomeprazole 40 mg, amoxicillin 1000 mg, and clarithromycin 500 mg, all bid
Number of subjects: 257
Study 21475971 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol (0.65 g/kg)
Number of subjects: 64
Study 21475971 — intervention group
Group type: COMPARATOR
Intervention: Non-alcoholic placebo beverage
Number of subjects: 64
Study 19994685 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog-day acupuncture and tortoise-shell moxibustion combined with pelvic floor muscle exercises
Number of subjects: 71
Study 19994685 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle exercises
Number of subjects: 71
Study 17848493 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin
Number of subjects: 8214
Study 17848493 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 8214
Study 14991092 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical treatment plus CPAP
Number of subjects: 89
Study 14991092 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment alone
Number of subjects: 89
Study 11574419 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg body wt)
Number of subjects: 9
Study 11574419 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose)
Number of subjects: 9
Study 9535249 — intervention group
Group type: EXPERIMENTAL
Intervention: PFP/PFP vaccine
Number of subjects: 29
Study 9535249 — intervention group
Group type: COMPARATOR
Intervention: Saline/PFP vaccine
Number of subjects: 29
Study 7912767 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily enteric-coated aspirin 300 mg
Number of subjects: 20
Study 7912767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3281173 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (60 mg p.o.)
Number of subjects: 10
Study 3281173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3281173 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine infusion (25 g i.v. for 30 min)
Number of subjects: 10
Study 30818765 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitration using 25-30% HNO3 for 30-40 minutes at room temperature
Number of subjects: 0
Study 28230607 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsule (Lactobacillus acidophilus ATCC B3208, 3×10^10 CFU; Bifidobacterium lactis DSMZ 32269, 6×10^10 CFU; Bifidobacterium bifidum ATCC SD6576, 2×10^10 CFU; Lactobacillus rhamnosus DSMZ 21690, 2×10^10 CFU) for 12 weeks
Number of subjects: 64
Study 28230607 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 64
Study 26388504 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SA)
Number of subjects: 46
Study 23263208 — intervention group
Group type: EXPERIMENTAL
Intervention: Group T (using ultrasound machine with onboard electronic tutorial)
Number of subjects: 35
Study 23263208 — intervention group
Group type: COMPARATOR
Intervention: Group S (using standard ultrasound machine)
Number of subjects: 35
Study 23263208 — intervention group
Group type: EXPERIMENTAL
Intervention: Group T
Number of subjects: 35
Study 23263208 — intervention group
Group type: COMPARATOR
Intervention: Group S
Number of subjects: 35
Study 22018124 — intervention group
Group type: EXPERIMENTAL
Intervention: Postplacental IUD
Number of subjects: 96
Study 22018124 — intervention group
Group type: COMPARATOR
Intervention: Delayed IUD
Number of subjects: 96
Study 18430855 — intervention group
Group type: EXPERIMENTAL
Intervention: 64-MDCT
Number of subjects: 38
Study 18430855 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 38
Study 18430855 — intervention group
Group type: EXPERIMENTAL
Intervention: 64-MDCT and MRI
Number of subjects: 38
Study 16595276 — intervention group
Group type: EXPERIMENTAL
Intervention: 6- to 8-hour, 7-lesson education experience with food preparation and tasting (EFNEP)
Number of subjects: 5111
Study 16595276 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5111
Study 14600570 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-dissociated p24 antigen (HD p24 Ag) assay
Number of subjects: 117
Study 14600570 — intervention group
Group type: COMPARATOR
Intervention: HIV-1 RNA levels quantified by the Amplicor HIV-1 Monitor assay
Number of subjects: 117
Study 10981842 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphasizing aspects of identity that differentiate from the comparison standard
Number of subjects: 0
Study 10981842 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 9181519 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (100 mg)
Number of subjects: 7
Study 9181519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 9181519 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen supplementation (0.625 mg/day)
Number of subjects: 7
Study 1286524 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.125 mg twice weekly
Number of subjects: 188
Study 1286524 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.5 mg twice weekly
Number of subjects: 188
Study 1286524 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.75 mg twice weekly
Number of subjects: 188
Study 1286524 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 1.0 mg twice weekly
Number of subjects: 188
Study 1286524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 4064569 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin octapeptide (CCK‐8)
Number of subjects: 5
Study 4064569 — intervention group
Group type: COMPARATOR
Intervention: Combination of CCK‐like peptide, caerulein, and secretin
Number of subjects: 5
Study 31905205 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline solution (PosiFlush®, group A)
Number of subjects: 241
Study 31905205 — intervention group
Group type: COMPARATOR
Intervention: Heparin (Fibrilin®, group B)
Number of subjects: 241
Study 30115086 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm formula (PF)
Number of subjects: 70
Study 30115086 — intervention group
Group type: COMPARATOR
Intervention: Pasteurized donor human milk (PDHM)
Number of subjects: 70
Study 27179402 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab + Docetaxel (Group A)
Number of subjects: 417
Study 27179402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab + Trastuzumab + Docetaxel (Group B)
Number of subjects: 417
Study 27179402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab + Trastuzumab (Group C)
Number of subjects: 417
Study 27179402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab + Docetaxel (Group D)
Number of subjects: 417
Study 27179402 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Pathological Complete Response (all groups combined)
Number of subjects: 417
Study 24811603 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline catheter (POWERWAND®)
Number of subjects: 0
Study 24811603 — intervention group
Group type: COMPARATOR
Intervention: PICC
Number of subjects: 0
Study 22619886 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcitriol 0.5 mcg twice weekly
Number of subjects: 91
Study 22619886 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral calcitriol)
Number of subjects: 91
Study 19560307 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence intervention based on Fisher & Fisher's Information‐Motivation‐Behavioral Skills Model
Number of subjects: 73
Study 19560307 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence intervention
Number of subjects: 73
Study 19560307 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interventions
Number of subjects: 73
Study 19560307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing fidelity monitoring with motivational interviewing
Number of subjects: 73
Study 19560307 — intervention group
Group type: EXPERIMENTAL
Intervention: Refill rate
Number of subjects: 73
Study 19560307 — intervention group
Group type: EXPERIMENTAL
Intervention: MEMS
Number of subjects: 73
Study 19560307 — intervention group
Group type: EXPERIMENTAL
Intervention: ACASI
Number of subjects: 73
Study 19560307 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence support from a consistent caring individual
Number of subjects: 73
Study 17589949 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal saline‐epinephrine injection (epinephrine group)
Number of subjects: 486
Study 17589949 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection (saline group)
Number of subjects: 486
Study 17589949 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 486